Efficacy
First line setting
Median progression-free survival for the docetaxel carboplatin arm was 15 months (95% CI 13.3 to 16.6 months) and 14.8 months (95% CI, 13.5 to 16.1 months) for the paclitaxel carboplatin arm (hazard ratio [HR] for docetaxel-paclitaxel =0.97, 95% CI, 0.83 to 1.13; p = 0.707). The two year survival rates with docetaxel-carboplatin 64.2% and paclitaxel-carboplatin were 59.5%.r
Kaplan–Meier probability of (A) Progression-free survival, and (B) Overall survival r
© Journal of the National Cancer Institute 2004
Second line setting
In the intent-to-treat population, the overall response rate was 72% (CR=64% and PR=8%). 12% of patients showed a stable disease and 8% showed disease progression.r